Pharming Group
PHAR
2 hedge funds and large institutions have $291K invested in Pharming Group in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
2% less capital invested
Capital invested by funds: $296K → $291K (-$4.86K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$11.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPA
1
Cowen Prime Advisors
New York
| $262K | – | – | – |
|
2
Morgan Stanley
New York
| $29.1K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$11.9K | -881 | Closed |
|
PHAR Hedge Fund Activity: Q2 2023 in Review
2 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q2 2023, worth a combined $291K — down 1.6% from $296K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PHAR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $11.9K sold.
- 2 institutional investors held Pharming Group (PHAR) as of Q2 2023, down from 3 in Q1 2023.
- Funds reported $291K of Pharming Group stock for Q2 2023, down 1.6% quarter-over-quarter.
- 0 funds opened new Pharming Group positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Pharming Group seller in Q2 2023 was UBS Group, an estimated $11.9K sold.
Based on aggregated 13F filings for Q2 2023.